EMV CAPITAL PLC - Final Results for the year to 31 December 2025

EMV Capital PLC delivered a strong 2025 investor update, reporting 14% growth in assets under management (AUM) to £112 million and a 17% increase in group revenue, driven by expanding corporate finance activity, recurring fund management fees, and portfolio value creation. The deep tech and life sciences investor highlighted significant progress in its scalable venture capital platform, with EMVC core revenue rising 31% to £3.2 million and core profitability improving through disciplined cost management and fair value gains across key portfolio companies. The company’s differentiated venture build strategy continued to generate momentum, creating approximately £10 million in fair value from under £1 million of deployed capital while attracting £12.5 million in third-party funding across high-growth businesses in AI, healthtech, semiconductors, space tech, and biotech. Management emphasized strong commercial traction in portfolio companies including AMR Bio, Sofant Technologies, and Wanda Health, alongside a growing order pipeline and institutional fundraising activity. EMV Capital also outlined its long-term growth strategy focused on expanding AUM toward £200 million, increasing recurring revenues, enhancing EBITDA potential, and driving future shareholder returns through exits, secondaries, and carried interest. With improving liquidity, an expanding investor syndicate, and increasing operational self-sufficiency, EMV Capital believes its current valuation significantly undervalues the underlying portfolio and long-term growth opportunity.